Health ❯ Healthcare ❯ Pharmaceuticals ❯ Weight Loss

Semaglutide

New Study Finds Nearly Fivefold Higher Reported ‘Eye Stroke’ Risk With Wegovy vs Ozempic

A retrospective FDA adverse‑event analysis reported the signal, prompting regulator warnings and calls for prospective studies.

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

Novo Nordisk Sues Hims & Hers to Halt Compounded Wegovy Copycats

Hims & Hers Halts $49 Compounded Wegovy Pill as FDA Tightens GLP-1 Rules

Anvisa Expands Wegovy and Ozempic Uses to Cardiovascular and Kidney Protection

BMJ Review Flags Rapid Weight Regain After GLP‑1 Stop as UK Approves Higher‑Dose Wegovy

UK ‘Postcode Lottery’ for Weight-Loss Jabs Persists as Generics Line Up for 2026

Triple-Dose Semaglutide Outperforms Standard Regimen in Weight-Loss Trials

Half of Semaglutide Users Quit Within a Year as Higher Dose Trials Show Bigger Losses, More Side Effects

Eli Lilly’s Oral Obesity Pill Triggers Stock Slide After Modest Weight-Loss Results

Tirzepatide Outperforms Semaglutide in Weight-Loss Trial

Semaglutide Shows Potential to Slow Aging and Reduce Mortality Rates

Semaglutide Drugs Show Potential Beyond Weight Loss

Surge in GLP-1 Drugs for Weight Loss Sparks Concerns Over Diabetes Treatment

UK Approves Wegovy for Reducing Heart Risks in Overweight Patients